<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530708</url>
  </required_header>
  <id_info>
    <org_study_id>MARS</org_study_id>
    <nct_id>NCT04530708</nct_id>
  </id_info>
  <brief_title>Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC</brief_title>
  <acronym>MARS</acronym>
  <official_title>Multicentre Phase III Study: Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Lung Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Lung Cancer Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis for this study is that addition of a moderate dose of radiotherapy to the&#xD;
      primary tumor and mediastinal nodes after three months of medical treatment could reduce the&#xD;
      tumor burden, partly as an abscopal effect, and thereby improving quality of life and&#xD;
      possible also prolonging survival for stage IV NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: To assess whether the addition of radiotherapy to the remaining thoracic&#xD;
      tumor burden following standard medical treatment results in a superior quality of life&#xD;
      measured with lung cancer symptom scale (LCSS) in patients with stage IV non-small cell lung&#xD;
      cancer. The comparison will be made at three months after randomization.&#xD;
&#xD;
      Secondary objectives: Overall survival, progression-free survival, toxicity and longitudinal&#xD;
      quality of life measurements.&#xD;
&#xD;
      Design: Multicentre, randomized, phase III trial. Patients will be registered for the study&#xD;
      up-front but randomization will be performed after evaluation of response, three months after&#xD;
      initiating medical treatment with chemotherapy/ chemo-immunotherapy or immunotherapy.&#xD;
      Randomization will be to thoracic radiotherapy or follow-up (1:1).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre randomized phase 3 trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in quality of life</measure>
    <time_frame>Three months after randomization</time_frame>
    <description>LCSS, lung cancer symptom scale. A scale from zero to one-hundred, higher number indicate worse symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>From randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
    <description>From randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of esophagitis, pneumonitis, dyspnea, fatigue, cough</measure>
    <time_frame>During follow-up , up to 24 months.</time_frame>
    <description>CTC (common toxicity criteria) version 4.0. Esophagitis, pneumonitis, dyspnea, fatigue, cough, worst grade.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Radiotherapy</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>A: Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal standard of care and follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Thoracic radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Addition of thoracic radiotherapy to 36 Gy after medical treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic radiotherapy</intervention_name>
    <description>36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.</description>
    <arm_group_label>B: Thoracic radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Stage IV disease&#xD;
&#xD;
          -  Previously untreated disease (before first line treatment)&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
          -  Performance status (WHO) 0-2&#xD;
&#xD;
          -  FEV1 (forced expiratory volume one second) ≥ 1 L or &gt;40% of predicted&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Platelet count ≥ 100,00/mm3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dl&#xD;
&#xD;
          -  WBC (White blod cells) ≥ 3,000/mm3&#xD;
&#xD;
          -  Kidney function allowing chemotherapy&#xD;
&#xD;
          -  Patients scheduled for standard platinum based chemotherapy, chemo-immunotherapy or&#xD;
             immunotherapy&#xD;
&#xD;
          -  Willing and able to comply with study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requirement for daily supplemental oxygen&#xD;
&#xD;
          -  Second primary malignancy within 3 years, except for any of the following which can be&#xD;
             included even if diagnosed within the past 3 years: Carcinoma in situ of the cervix,&#xD;
             nonmelanoma skin cancer, history of low-grade (Gleason score ≤ 6) localized prostate&#xD;
             cancer, definitely treated stage I breast cancer, other malignancy that was diagnosed&#xD;
             and definitely treated ≥ 3 years ago with no subsequent evidence of recurrence&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical condition, including any of the&#xD;
             following:&#xD;
&#xD;
          -  Angina pectoris&#xD;
&#xD;
          -  Congestive heart failure within the past 3 months, unless LVEF (left ventricular&#xD;
             ejection fraction) &gt; 40%&#xD;
&#xD;
          -  Myocardial infarction within the past 6 months&#xD;
&#xD;
          -  Clinically significant infection&#xD;
&#xD;
          -  Psychiatric illness or social situation that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  EGFR (epidermal growth factor receptor) mutation or ALK (anaplastic lymphoma kinas) -&#xD;
             rearrangement detected&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Nyman, Ass.prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Björk-Eriksson, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Regionalt Cancercentrum Väst</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Nyman, Ass.prof.</last_name>
    <phone>0046313421000</phone>
    <phone_ext>27927</phone_ext>
    <email>jan.nyman@oncology.gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Hallqvist, MD, PhD</last_name>
    <phone>0046739845114</phone>
    <email>andreas.hallqvist@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology, Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <state>Norrland</state>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Johansson, MD PhD</last_name>
      <phone>0046703711414</phone>
      <email>mikael.johansson@onkologi.umu.se</email>
    </contact>
    <investigator>
      <last_name>Mikael Johansson, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholm County</state>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Signe Friesland, MD PhD</last_name>
      <email>signe.friesland@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Gunnar Wagenius, MD PhD</last_name>
      <email>gunnar.wagenius@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Signe Friesland, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gunnar Wagenius, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Nyman, Ass prof</last_name>
      <phone>0046313427927</phone>
      <email>jan.nyman@oncology.gu.se</email>
    </contact>
    <contact_backup>
      <last_name>Bengt Bergman, Ass.prof.</last_name>
      <phone>0046706187880</phone>
      <email>bengt.bergman@vgregion.se</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Hallqvist, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Rzepecki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hillevi Rylander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hedda Haugen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Lundin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mihalj Seke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Nyman, Ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina Lamberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hirsh Koyi, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swedish Lung Cancer Study Group</investigator_affiliation>
    <investigator_full_name>Ass. Prof. Jan Nyman</investigator_full_name>
    <investigator_title>Head of Swedish Lung Cancer Study Group, Ass. Prof.</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT04530708/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

